Our research is focused on developing small molecules of therapeutic value in neurodegenerative diseases and cancers. Our goal is not only to design and synthesize bioactive molecules to help deciphering important biological mechanisms but also to develop drug candidates. These compounds are rationally designed through molecular modeling and medicinal chemistry knowledge. The drug optimization follows the iterative process described below.

With a proven expertise in medicinal and synthetic organic chemistry, our team works in close collaboration with pharmacologists, biologists and clinicians. Our efforts culminated in the discovery of a marketed drug (Agomelatine, melatonergic antidepressant) and a drug candidate currently in phase 1 clinical trials in the treatment of Alzheimer’s disease. Current research projects include:

  • the study of a biological target involved in the degradation of altered and misfolded proteins in neurodegenerative diseases,
  • the development of antagonists of the adenosine A2a receptor implicated in Alzheimer's and Parkinson's Diseases and,
  • the study of some important protein-protein interactions for the treatment of cancers.